

The Manager
Company Announcements Office
ASX Limited

ST VINCENT'S HOSPITAL COMPLETES APAS® INDEPENDENCE IN SITU EVALUATION

- Centre of excellence laboratory tests automation efficiency in busy real-life setting
- Successfully achieved evaluation performance targets with laboratory efficiencies realised

Adelaide, Australia, 29 November 2017: Australian medical technology company LBT Innovations Limited (ASX: LBT) and joint venture company Clever Culture Systems AG (CCS) have successfully completed an independent evaluation of their APAS® Independence instrument at St Vincent's Hospital in Melbourne. The evaluation is the first in situ installation of the instrument globally.

APAS® is a breakthrough artificial intelligence technology for the automated imaging, image analysis, interpretation and reporting of growth on microbiology plates after incubation. The APAS® Independence, which is about the size of a large photocopier, improves the diagnostic efficiency of microbiology laboratories and enables faster reporting of infectious diseases. The US FDA-cleared technology is based on LBT's Australian-developed intelligent imaging and machine learning software.

Placement in St Vincent's Hospital, a highly regarded centre of excellence, enabled the evaluation of the instrument's performance within a diagnostic pathology laboratory, in an "end user" setting with scientists using the APAS® Independence instrument over a six- week period.

The evaluation included over 3000 urine samples that were automatically read and interpreted by the APAS® Independence instrument.

LBT Scientific Director Dr Steven Giglio is an experienced microbiologist who worked with St. Vincent's Hospital in setting up the evaluation. "It was a pleasure to work with the dedicated team at St Vincent's Hospital who conducted the evaluation completely independently and demonstrated a high level of engagement with the instrument. The instrument performed as expected during the evaluation and was successful in triaging the negative plates out of the workflow, allowing microbiologists to focus on positive plates only. In addition, the APAS® Independence facilitated significant upstream benefits in specimen processing, realising further efficiencies from the introduction of this instrument. A significant amount of data has been generated which will form the basis for several scientific presentations and publications to disseminate these findings to the scientific community" said Dr Giglio.

This independent evaluation by St Vincent's Hospital confirms the utility of the instrument in a clinical setting. Of note are the additional efficiencies gained at the specimen processing step, which we expect to be representative of other laboratories around the world.

LBT CEO and Managing Director Brent Barnes, says "it is pleasing the instrument performed successfully in a real world setting in this global first trial. The evaluation of the instrument provides clear validation that the foundational technology works and the instrument does deliver efficiencies in a laboratory."

Feedback summary from St Vincent's Hospital Microbiology laboratory trial:

- The instrument works and performance targets were successfully met
- Laboratory efficiencies were observed
- Installation was easy with no special requirements as the instrument is simply wheeled into a lab and plugged in
- High level of user engagement
- User interface intuitive and easy to use.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has two world class-leading products in microbiology automation: MicroStreak®, which provides automated culture plate streaking and Automated Plate Assessment System (APAS®). Based on LBT's intelligent imaging and interpretative software, US FDA-cleared APAS® automates imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a joint venture Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH to commercialise APAS® products. LBT's third product WoundVue® is in early development; this is a proposed automated solution to assist in the management of chronic wounds.

CONTACTS

LBT Innovations	Media Relations
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 (0)8 8227 1555 E: info@lbtinnovations.com	Sarah Kemter Monsoon Communications Tel: +61 (0)3 9620 3333 M: +61 (0) 407 162 530 E: sarahk@monsoon.com.au